Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance in formulations, particularly in the US and European markets. However, ARV revenues declined, and API revenues saw a marginal dip.
Related Posts
Airbus cuts over 2,000 jobs amidst competition from Elon Musk’s Starlink
Airbus is cutting roughly 2,000 jobs, about 5% of its Defence and Space division, due to losses in its satellite business and increased competition. No […]
MSDE partners with Swiggy to provide skilling, employment opportunities
The Ministry of Skill Development and Entrepreneurship has teamed up with Swiggy to offer skilling and employment opportunities in its food delivery and quick commerce […]